922 related articles for article (PubMed ID: 15986066)
21. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life.
Nair N; Gans H; Lew-Yasukawa L; Long-Wagar AC; Arvin A; Griffin DE
J Infect Dis; 2007 Nov; 196(9):1339-45. PubMed ID: 17922398
[TBL] [Abstract][Full Text] [Related]
22. [A seroconversion study of the measles component of the MMR vaccine in adolescents of the town of Sabrosa].
Gonçalves G; Tavares F; de Andrade HR
Acta Med Port; 1998 Dec; 11(12):1079-84. PubMed ID: 10192981
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults.
Kakoulidou M; Ingelman-Sundberg H; Johansson E; Cagigi A; Farouk SE; Nilsson A; Johansen K
Vaccine; 2013 Jan; 31(4):711-7. PubMed ID: 23174196
[TBL] [Abstract][Full Text] [Related]
24. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination.
Ovsyannikova IG; Jacobson RM; Vierkant RA; Jacobsen SJ; Pankratz VS; Poland GA
J Infect Dis; 2005 Feb; 191(4):515-9. PubMed ID: 15655774
[TBL] [Abstract][Full Text] [Related]
25. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
Celikbas A; Ergonul O; Aksaray S; Tuygun N; Esener H; Tanir G; Eren S; Baykam N; Guvener E; Dokuzoguz B
Am J Infect Control; 2006 Nov; 34(9):583-7. PubMed ID: 17097453
[TBL] [Abstract][Full Text] [Related]
26. Seroprevalence of rubella infection after national immunization program in Taiwan: vaccination status and immigration impact.
Wang IJ; Huang LM; Chen HH; Hwang KC; Chen CJ
J Med Virol; 2007 Jan; 79(1):97-103. PubMed ID: 17133552
[TBL] [Abstract][Full Text] [Related]
27. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026
[TBL] [Abstract][Full Text] [Related]
28. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
[TBL] [Abstract][Full Text] [Related]
29. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
30. Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium.
Theeten H; Hutse V; Hens N; Yavuz Y; Hoppenbrouwers K; Beutels P; Vranckx R; Van Damme P
Epidemiol Infect; 2011 Apr; 139(4):494-504. PubMed ID: 20587123
[TBL] [Abstract][Full Text] [Related]
31. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA
Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054
[TBL] [Abstract][Full Text] [Related]
32. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept.
Borte S; Liebert UG; Borte M; Sack U
Rheumatology (Oxford); 2009 Feb; 48(2):144-8. PubMed ID: 19074187
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.
Avijgan M; Hafizi M; Moghni M; Kheiri S; Esteghamati A; Sarikhani S
East Afr J Public Health; 2011 Jun; 8(2):88-91. PubMed ID: 22066292
[TBL] [Abstract][Full Text] [Related]
35. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design.
Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Poland GA
Vaccine; 2007 Apr; 25(16):3090-100. PubMed ID: 17280755
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
37. A 24-year review on the epidemiology and control of measles in Singapore, 1981-2004.
Ong G; Hoon HB; Ong A; Chua LT; Kai CS; Tai GK
Southeast Asian J Trop Med Public Health; 2006 Jan; 37(1):96-101. PubMed ID: 16771219
[TBL] [Abstract][Full Text] [Related]
38. Sero-response to measles vaccination at 12 months of age in Saudi infants in Qassim Province.
Khalil MK; Nadrah HM; Al-Yahia OA; Al-Saigul AM
Saudi Med J; 2008 Jul; 29(7):1009-13. PubMed ID: 18626531
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of measles antibodies before and after vaccination in previously unvaccinated children of the Cordillera Province (Santa Cruz Department, Bolivia).
Guglielmetti P; Bianchi Bandinelli ML; Bartoloni A; Gamboa H; Roselli M; Valensin PE
J Trop Med Hyg; 1994 Aug; 97(4):231-5. PubMed ID: 8064946
[TBL] [Abstract][Full Text] [Related]
40. Sero-epidemiology of measles and mumps in Korea: impact of the catch-up campaign on measles immunity.
Kim SS; Han HW; Go U; Chung HW
Vaccine; 2004 Dec; 23(3):290-7. PubMed ID: 15530670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
